This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD)

Tipranks - Tipranks - Thu Aug 6, 8:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD) with bullish sentiments.

Claim 55% Off TipRanks

InfuSystem Holdings (INFU)

In a report released today, Anderson Schock from B. Riley Securities maintained a Buy rating on InfuSystem Holdings, with a price target of $20.00. The company’s shares closed last Tuesday at $12.32.

According to TipRanks.com, Schock is a 4-star analyst with an average return of 11.8% and a 61.8% success rate. Schock covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Orchestra BioMed Holdings, and Clinigence Holdings. ;'>

InfuSystem Holdings has an analyst consensus of Strong Buy, with a price target consensus of $18.75, representing an 84.9% upside. In a report issued on July 21, TipRanks – DeepSeek also upgraded the stock to Buy with a $10.00 price target.

See today’s best-performing stocks on TipRanks >>

Arrowhead Pharmaceuticals (ARWR)

B. Riley Securities analyst Madison Elsaadi reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $123.00. The company’s shares closed last Tuesday at $89.59.

According to TipRanks.com, Elsaadi is a 5-star analyst with an average return of 40.3% and a 58.7% success rate. Elsaadi covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Eton Pharmaceuticals, and Spruce Biosciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $103.05 average price target, implying a 18.4% upside from current levels. In a report issued on July 21, J.P. Morgan also maintained a Buy rating on the stock with a $95.00 price target.

Gilead Sciences (GILD)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Gilead Sciences today and set a price target of $162.00. The company’s shares closed last Tuesday at $135.25.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 5.6% and a 57.8% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Parabilis Medicines, Inc., Ultragenyx Pharmaceutical, and Alto Neuroscience, Inc. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $159.00, a 21.2% upside from current levels. In a report issued on July 22, Bernstein also maintained a Buy rating on the stock with a $160.00 price target.

Read More on INFU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).